Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Syros Pharmaceuticals (SYRS)
NASDAQ:SYRS
Syros Pharmaceuticals (SYRS) Stock Price & Analysis
641 Followers
SYRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.67 - $14.30
Previous Close$2.77
Volume57.21K
Average Volume (3M)135.68K
Market Cap
$56.23M
Enterprise Value-$82.50M
Total Cash (Recent Filing)$202.30M
Total Debt (Recent Filing)$63.57M
Price to Earnings (P/E)-0.2
Beta0.42
Next Earnings
May 11, 2023EPS Estimate
-$1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.77
Shares Outstanding20,300,419
10 Day Avg. Volume156,881
30 Day Avg. Volume135,676
Standard Deviation0.24
R-Squared0.14
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.44
Price to Sales (P/S)3.74
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-5.54
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.94
Forecast
1Y Price Target
$24.00Price Target Upside788.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Syros Pharmaceuticals News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SYRS FAQ
What was Syros Pharmaceuticals’s price range in the past 12 months?
Syros Pharmaceuticals lowest stock price was $2.67 and its highest was $14.30 in the past 12 months.
What is Syros Pharmaceuticals’s market cap?
Currently, no data Available
When is Syros Pharmaceuticals’s upcoming earnings report date?
Syros Pharmaceuticals’s upcoming earnings report date is May 11, 2023 which is in 43 days.
How were Syros Pharmaceuticals’s earnings last quarter?
Syros Pharmaceuticals released its earnings results on Mar 02, 2023. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$1.225 by $1.055.
Is Syros Pharmaceuticals overvalued?
According to Wall Street analysts Syros Pharmaceuticals’s price is currently Undervalued.
Does Syros Pharmaceuticals pay dividends?
Syros Pharmaceuticals does not currently pay dividends.
What is Syros Pharmaceuticals’s EPS estimate?
Syros Pharmaceuticals’s EPS estimate is -$1.05.
How many shares outstanding does Syros Pharmaceuticals have?
Syros Pharmaceuticals has 20,300,419 shares outstanding.
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Syros Pharmaceuticals reported an EPS of -$0.17 in its last earnings report, beating expectations of -$1.225. Following the earnings report the stock price went up 2.732%.
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
Among the largest hedge funds holding Syros Pharmaceuticals’s share is Flagship Pioneering Inc.. It holds Syros Pharmaceuticals’s shares valued at 4M.
---
Syros Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (788.89% Upside)
$24.00 (788.89% Upside)
Blogger Sentiment
Neutral
SYRS Sentiment 50%
Sector Average 68%
Sector Average 68%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.36%
12-Months-Change
Fundamentals
Return on Equity
-88.90%
Trailing 12-Months
Asset Growth
33.65%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
---
Top 5 ETFs holding SYRS
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold SYRS. The ETFs are listed according to market value of SYRS within the ETF
---
---